Digestive Diseases Research Seminar
Presented by Yale School of Medicine,
Department of Internal Medicine, and Section of Digestive Diseases

YaleCME
CONTINUING MEDICAL EDUCATION

Polycystic liver disease: Molecular genetic basis, clinical spectrum, and ongoing gene-based research

Whitney Besse, MD

Assistant Professor of Medicine, Division of Nephrology
Department of Medicine, Yale School of Medicine

Tuesday, September 14, 2021

5:00 - 6:00 pm

https://zoom.us/j/96123103886?pwd=cHpVZFo0TlF4QWpCVHA1UUhKdE4yZz09

Host: Silvia Vilarinho, MD, PhD

To record your attendance to this activity, text the Activity Code (**29413**) for your RSS activity to **203-442-9435**. You will receive a message back that verifies your activity attendance has been recorded for CME credit.

There is no corporate support for this activity. Accreditation: The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. **Target Audience**: YSM faculty, fellows, nurses, residents, medical students, staff, and other health care providers. **Designation Statement**: The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity. **Needs assessment**: Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disease and has incidence of 1:400-1:1000. Over 93% of patients with ADPKD have polycystic livers. We also now have an improved understanding of the related phenotype of isolated polycystic liver disease (PCLD). Autosomal recessive polycystic kidney disease (ARPKD) also has a liver phenotype that is often the most clinically relevant component of the disease. We have recently described polycystic liver disease in ARPKD carriers. These diseases are often studied by Nephrologists, but clinical care may be by Nephrologists and Hepatologists depending on each patient's predominant complications. There is a need for increased education and collaboration regarding the study and clinical care of polycystic and fibrotic liver phenotypes in these diseases. **Objectives:** 1) To understand the genetic and mechanistic basis of the spectrum of autosomal dominant polycystic kidney and liver phenotypes; 2) To learn recent advances in understandings of liver phenotypes in autosomal recessive polycystic kidney disease patients and heterozygous carriers; 3) To learn about and discuss collaborations involving ongoing research in polycystic liver disease at Yale. **Faculty Disclosures**: W Besse – None; S Vilarinho – None. It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs. **This course will fulfill the licensure requirement set forth by the State of Connecticut.**